Thinking beyond probiotics with personalised and total microbiome support
BioMed Technology Holdings, Hong Kong’s microbiome startup, has raised $2 million in its latest oversubscribed seed round from Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA and The International Medical Co. (TIMC). The new funds will allow the company to further research and develop biotech-driven solutions that help consumers get their “best-fit” microbiome health management plan for wellness enhancement as well as to realise its expansion in mainland China and Asia. BioMed’s unique, revolutionary healthcare delivery bodes well for the future of personalised care and precision medicine.
On the B2C front, the distribution network of BioMed’s brand PGut has covered over 300 retail outlets, including Mannings, Pricerite, JustMed and SodaMall. The launch of the PGut E3 upgraded series is a move to lead the way in the market by introducing postbiotics to the formulas.
According to Arizton’s market report, the probiotics supplements market size is expected to reach $9 billion by 2025. The Asia Pacific market is estimated to witness the fastest growth in the coming years. With the outbreak of COVID-19, the demand for personalised nutrition and immune-based products is expected to surge.
